Movement in the right direction with test volumes being up 36% on PCP. Substantial improvement in CXB sensitivity with the "enhanced" version appears to be received very well by the urology community and a deadline for the KP EMR system integration of March. Only nasty hanging around is the Novitas LCD.
2.1 m shares traded yesterday. The largest volume of any company that I could see. Any insights/comments?
No insights. Just continuing to hold and wait for the Novitas announcement and the results of the KP system integration.
Success on both counts will have immediate positive impacts on the SP.
Onwards and upwards.
The bladder cancer diagnostic firm Pacific Edge is celebrating 20 years since it listed on the NZX, growing significantly over that time without ever making a bottom-line net profit.
The bladder cancer diagnostic firm Pacific Edge is celebrating 20 years since it listed on the NZX, growing significantly over that time without ever making a bottom-line net profit.
and the important bit -
Chief executive Peter Meintjes said the NZX listing had helped the company raise growth capital over the past couple of decades, which has been key to its success.
“ At the top of every bubble, everyone is convinced it's not yet a bubble.”
Chief executive Peter Meintjes said the NZX listing had helped the company raise growth capital over the past couple of decades, which has been key to its success.
But not so successful for the shareholders who eagerly jumped on the bandwagon and parted with ever more money in PEB's upsized CR ($1.35 price) in 202.
Reply With Quote
Originally Posted by Mel
Bookmarks